PREVENTIVE EFFECTS OF THE AQUEOUS EXTRACT OF CINNAMOMUM ZEYLANICUM BARK ON DEXAMETHASONE INDUCED INSULIN RESISTANCE IN WISTAR ALBINO RATS by CH, Rajasekhar et al.
International Journal of Clinical and Biomedical Research 
Original Article 
 
PREVENTIVE EFFECTS OF THE AQUEOUS EXTRACT OF CINNAMOMUM 
ZEYLANICUM BARK ON DEXAMETHASONE INDUCED INSULIN RESISTANCE IN 
WISTAR ALBINO RATS  
RAJASEKHAR CH1, *NAGENDRANAYAK IM2, RAJESH B1, KOKILA B NAGRAJU1, GURUPRASAD N 
BANAVASI2, HEMANTH KUMAR V3 
1Dept of pharmacology, KVG Medical College& Hospital, Sullia, D.K, Karnataka.2Dept of Pharmacology, KS Hegde Medical Aacademy, Mangalore, Karnataka. 
3Dept of Pharmacology, Al-ameen Medical College, Bijapur 
*Corresponding author email: nittenayakim@gmail.com 
Received: 25th July 2015, Accepted: 15th Aug 2015. 
 
ABSTRACT 
Objectives: To evaluate the preventive effects of aqueous extract of Cinnamomum zeylanicum bark on dexamethasone induced insulin 
resistance and to compare it with rosiglitazone. Methods: The animals were categorized into two series of dexamethasone (dexamethasone 
4mg/kg, dexamethasone 8mg/kg series) with 5 groups in each [plain control, dexamethasone 4/8mg/kg as per series, rosiglitazone 8mg/kg 
and 16mg/kg, cinnamon bark extract (CZE) 250mg/kg BW]. Six animals were studied in each group. In a12 day study period, rosiglitazone 
and CZE groups received respective drug treatments and dexamethasone dosing (4mg/kg or 8mg/kg) was started from day 7onwards. On 
day 12, fasting blood, urine and post IPGTT blood samples were collected and processed for glucose, insulin and ketone estimations. 
Results: In both series, CZE 250mg/kg treatment showed significant reduction in mean fasting glucose and insulin compared to 
rosiglitazone 8mg/kg and 16mg/kg groups and dexamethasone controls (4mg/kg, 8mg/kg groups) (P<0.05). The fall in glucose and insulin 
levels observed with CZE treatment at 30, 60 min post IPGTT in both series were significant compared to rosiglitazone and dexamethasone 
treatment groups (P<0.05). Glycosuria and ketonuria were absent in CZE groups, whereas these were reduced significantly in rosiglitazone 
groups compared to dexamethasone groups (P<0.05). Conclusion: The aqueous extract of C. zeylanicum bark prevented the insulin 
resistance as evidenced by reduced fasting and post IPGTT glucose and insulin levels in steroid induced insulin resistance model. 
KEYWORDS: Glucose uptake, Cinnamon bark, Rosiglitazone, Hyperinsulinemia, Hyperglycemia. 
INTRODUCTION 
Insulin resistance is known as a state where normal or elevated 
insulin level produces a reduced biological response and is 
commonly associated with type II diabetes mellitus. It is 
characterized by hyperinsulinemia and hyperglycemia due to 
reduced overall peripheral glucose utilization in the body. 
Although biguanides and thiazolidinediones (TZDs) are the 
mainstay of the drug therapy; certain adverse effects limit their 
use in long term management. 
Cinnamon (Cinnamomum zeylanicum Nees), the evergreen tree 
of tropical area, a member of the family Lauraceae, is being used 
in day to day routine as a spice and condiment in India. It has 
good anti-inflammatory, anti-oxidant, anti-ulcer, anti-microbial, 
hypoglycemic and hypolipidemic potentials. [1] Studies on 
cinnamon have revealed that chief constituents like 
cinnamicacid, cinnamaldehyde, MHCP and cinnamate present 
in the extract are known to be responsible for its anti-
hyperglycemic effect. [2, 3] MHCP closely mimics insulin activity 
and works synergistically with insulin in cells.[4] However, the 
hypoglycaemic activity of C. zeylanicum bark has been studied 
in rodents, but its effect on steroid  induced insulin resistance is 
yet to be demonstrated in vivo. The purpose of the present study 
is to investigate the preventive effects of aqueous extract of C. 
zeylanicum bark on dexamethasone induced insulin resistance 
and compare it with rosiglitazone. 
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METHODS AND METERIALS 
Animals 
The study was performed on male Wistar Albino rats weighing 
around 230-270gms. Prior to the study, all the animals were 
housed and maintained at 22-24°C temperature, under 12-h 
light: 12-h dark cycle with free access to food and water. 
Approval has been taken from the Institutional Animal Ethics 
Committee (Letter no: 798/2011) and all procedures were 
conducted according to the revised guidelines of CPCSEA Act, 
1960 India. 
Grouping of animals 
As shown in Table no: 1 all the animals selected for the study 
were divided into 8 major treatment groups of 6 animals in each 
group and one plain control. Except plain control, remaining 
groups were equally suited in to D4 and D8 series. 
Table 1. Grouping of animals 
Dexamethasone 4mg/kg 
(D4 Series) 
Dexamethasone 8mg/kg 
(D8 Series) 
Plain control – (Vehicle) 
Vehicle+Dexamethasone 
4mg/kg(Dexa control) 
Vehicle+Dexamethasone 
8mg/kg (Dexa control) 
Rosiglitazone 
8mg/kg+Dexa4mg/kg 
Rosiglitazone 
8mg/kg+Dexa8mg/kg 
Rosiglitazone 
16mg/kg+ Dexa4mg/kg 
Rosiglitazone 
16mg/kg+ Dexa8mg/kg 
Cinnamonextrct  250mg/kg  + 
Dexa4mg/kg 
Cinnamonextract 250mg/kg 
+Dexa8mg/kg 
Plant material and extraction 
Cinnamomum zeylanicum (dalchiniin Kannada) is commonly 
known as cinnamon, the bark was collected from the pharmacy 
department at KVG Ayurvedic Medical College & Hospital, 
Sullia, Karnataka, in the month of December 2012. The plant 
was identified and authenticated by a Botanist from Nehru 
Memorial College, Sullia, Dakshina Kannada, India and 
voucher specimen (No. SP-159: 22/1/2013) was preserved for 
future reference. The bark was finely powdered and then 
subjected to successive extraction in a Soxhlet apparatus using 
distilled -water at 80°C temperature. The yield of aqueous 
extract was concentrated in a rotary evaporator at reduced 
pressure and the water was allowed to evaporate completely. [5] 
The total yield was 6.1% and it was picked up and stored in cool 
and dry bath, which was further employed in the study. 
Drugs and doses 
All drug doses were selected based on a pilot study conducted 
in a small group of animals. 
Dexamethasone injections 4mg/kg and 8mg/kg body weight/day 
i.p were chosen. C. zeylanicum bark aqueous extract solution 
was prepared at a concentration of 250mg/ml with distilled 
water and a dose of 250mg/kg BW orally was given to the 
respective groups. A pure fine powdered form of rosiglitazone 
was purchased from Sigma labs, Rajendra traders, Dharwad, 
Karnataka. Drug solution was prepared by using 2% gum acacia 
solution. 8mg/kg and 16mg/kg of rosiglitazone were given 
orally to the respective groups. 
 
Figure 1. Study design 
Except dexamethasone, all the animals in all the groups received 
respective drugs daily throughout the study period (12 days). 
Treatment with dexamethasone was started from day 7 to day 
12.  Each rat was allowed to have 100gm of standard food pellets 
and 100 ml of water daily up to 11th day evening, followed by 
overnight fasting with free access to water alone. On 12th day 
morning, all physical parameters were recorded and drugs were 
given two hours prior to collecting blood by retro orbital sinus 
puncture method. The collected blood samples were centrifuged 
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(4000 RPM/20min) and the serum was processed for 
biochemical estimations (fasting glucose, insulin) (Figure 1). 
Intra peritoneal (i.p) glucose tolerance test (IPGTT) 
After 16 hours of fasting, blood samples from all the animals 
were collected followed by administration of glucose i.p 
(2gm/kg body weight). The blood samples were collected again 
at intervals of 30min, 60min and 120 min and then processed for 
glucose and insulin levels [6]. 
Estimation of serum glucose 
GOD-PAP method was employed to determine the serum 
glucose. The values were measured as mg/dl and were presented 
as Mean±SD. [7] 
Estimation of serum insulin 
Rat ultra sensitive ELISA insulin kit [8] was purchased from 
Crystal Chem labs, New Delhi. A high range assay (1-64ng/ml) 
was performed by using provided reagents and serum samples 
to determine the insulin values. To the Elisa frame, the antibody 
coated micro plates reagent which was marked 'A' were affixed. 
95µl of the sample diluent which was marked 'G' were dispensed 
per each well. 5 µl of the sample was pipetted out into each well.  
The micro plate was incubated for 2 hours at 4°C. After 
incubation, each well is washed with wash buffer for 5 times. 
100 µl of anti insulin enzyme conjugate was dispensed per well 
and the micro plate was incubated for 30 min at room 
temperature. Each well was washed 7 times with wash buffer. 
100 µl of enzyme substrate solution which was marked 'E' was 
dispensed per well. The micro plate was now incubated at room 
temperature for 10 min in light free area. The enzyme reaction 
was terminated by adding 100 µl of enzyme reaction stop 
solution marked 'F' per well. Optical density values were 
estimated using standard curves. The obtained optical density 
values were converted into its original insulin values (ng/ml) by 
subjecting to linear regression equation in MS Excel 2007 
version. The values were presented as Mean±SD. 
Urine glucose and ketones 
The fasting samples of urine were collected on day 12th morning 
in sample containers and presence of glucose and ketones were 
determined by (uristix) dip stick method. [9] The amount of 
glucose and ketones was measured in mmol/L. [10] 
STATISTICAL EVALUATION 
All the data were represented as Mean ±S.D and was subjected 
to One-Way ANOVA followed by Scheffe multiple comparison 
Post Hoc test in SPSS version 19. Level of significance was set 
at 5% and P≤0.05 was considered as statistically significant. 
RESULTS 
Fasting serum glucose and insulin 
The comparative effects of the C. zeylanicumand 
rosiglitazoneon hyperinsulinemia and hyperglycemia induced 
by dexamethasone are shown in Table 2. CZE250mg/kg 
significantly reduced fasting glucose and insulin levels 
compared to dexamethasone control and rosiglitazone 8, 
16mg/kg groups in both D4 and D8 series (P<0.05). These 
effects were not significant between different doses of standard 
drug treatment (Rosiglitazone 8,16mg/kg) (P>0.05) (Table 2). 
Post IPGTT serum glucose and insulin 
The post IPGTT values of serum glucose and insulin are shown 
in Figure 2A-D.  CZE 250mg/kg and rosiglitazone treatments 
improved glucose intolerance compared to dexamethasone 
control group in both D4 and D8 series (P<0.05). On intra-
peritoneal injection of glucose (2g/kg body weight) the mean 
blood glucose levels in plain control and CZE250mg/kg 
treatment group did not differ from each other in D4  as well as 
D8 series (P>0.05). The mean blood glucose levels in CZE 
250mg/kg showed significant differences at 30 and 60 min 
compared to rosiglitazone 8mg and 16mg/kg treatment in D4 
series and  CZE250mg/kg treatment in D8 series showed a 
significant difference at all intervals compared to both doses of 
rosiglitazone treatment (P<0.05). There was no significant 
difference in glucose values at respective intervals between two 
standard doses of rosiglitazone in both D4 and D8 series 
(P>0.05) (Table 3A). 
The mean insulin levels in CZE250 mg/kg showed significant 
difference at 30, 120min when compared to plain control in D4 
series (P<0.05). Nonetheless, there was no significant difference 
observed in D8 series at respective intervals (P>0.05). CZE250 
mg/kg showed a significant difference with rosiglitazone 
16mg/kg at 60min and both 8,16mg/kg of rosiglitazone at 120 
min in D4 series (P<0.05). The mean insulin values of CZE250 
mg/kg significantly reduced at 30, 60 and 120min when 
compared with rosiglitazone in D8 series (P<0.05). The 
maximum hypoglycaemic and hypoinsulinic effects were 
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observed in CZE250mg/kg treatment at 30 min post IPGTT in 
D4 and D8 series (Table 3B). 
Urine glucose and ketones 
The description and comparisons of urine glucose and ketones 
are represented in table 4. Glycosuria and ketonuria were absent 
in the CZE group in both D4 and D8 series, but there was a 
significant decrease in urine glucose in rosiglitazone 8, 16mg/kg 
treatment groups when compared to dexa control group 
(P<0.05). However, there was a significant decrease of urine 
glucose in rosiglitazone 16mg/kg compared to 8mg/kg in both 
D4 and D8 series (P>0.05). Urine ketones were absent in 
rosiglitazone 8 and 16mg when compared to dexa control group 
in D4 series. In D8 series rosiglitazone 8 and 16mg significantly 
lowered the ketonuria compared to dexa control group (P<0.05) 
(Table 4). 
 
Table.2.Differences in means of fasting glucose (mg/dl) and 
insulin (ng/ml) values on day 12 in Dexamethasone 4 and 8 
mg/kg series 
n=6 
Group 
Fasting Glucose 
D4 series         D8 series 
Fasting insulin 
D4 series     D8 series 
Plain 
control 
77.2±3.6 77.2±3.6 0.9±0.2 0.9±0.2 
Dexa 
control 
190.5±2.6 274.7±3.9 14.0±3.0 19.1±4.1 
Rosi 
8mg/kg 
108.7±3.5*be 125.9±4.4*abe 3.4±0.4*b 7.3±0.8*abde 
Rosi 
16mg/kg 
112.6±6.2*ab
e 
122.8±5.8
*abe
 3.8±0.3
*be
 5.4±0.5
*bce
 
CZE 
250mg/k
g 
84.6±7.7*bcd 96.3±5.5*bcd 1.1±0.5*bcd 2.3±0.7*bcd 
Note: *= significant at 5 % level (P<0.05), a= plain control; b= 
Dexa control; c= Rosiglitazone 8mg/kg; d= Rosiglitazone 
16mg/kg; e= C. zeylanicum bark extract 250mg/kg. 
 
 
 
Figure: 2 Post IPGTT glucose and insulin values on day 12 in Dexamethasone 4 and 8 mg/kg series 
2A 2C 
2B 2D 
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Note: Figure: 2 Post IPGTT glucose and insulin values on day 12 in Dexamethasone 4mg and 8mg/kg series, (2A) Post IPGTT glucose 
levels in D4 series, (2B) Post IPGTT insulin levels in D4 series, (2C) Post IPGTT glucose levels in D8 series, (2D) Post IPGTT insulin 
levels in D8 series. 
Table 3A. Differences in means of post IPGTT glucose and insulin levels on day 12 in dexamethasone 4mg/kg series (D4)
 
Table 3B. Differences in means of post IPGTT glucose and insulin levels on day 12 in dexamethasone 8mg/kg series (D8) 
Group 
n=6 
0min 
G                 I 
30min 
G                 I 
60min 
G                 I 
120min 
G                 I 
PC 83.3±7.9 0.7±0.0 147.8±3.9 5.7±1.4 131.9±9.5 4.6±1.8 100.8±5.4 2.6±0.5 
D8/kg 280.7±23.7 20.2±8.6 382.3±28.8 26.6±7.3 350.7±14.2 22.7±8.6 269.5±12.0 16.6±4.4 
R8/kg 
130.3±13.2 
*abe 
6.1±3.1 
*abde 
173.1±9.5 
*abe 
9.3±4.1 
*abe 
142.7±7.3 
*be 
7.5±2.2 
*abe 
126.9±6.2 
*abe 
4.9±0.7 
*abe 
R16/kg 
125.8±6.9 
*abe 
4.4±1.0 
*abce 
177±10.7 
*abe 
8.8±2.3 
*abe 
153.9±8.4 
*be 
6.8±2.0 
*abe 
128.8±7.8 
*abe 
5.1±1.7 
*abe 
CZE 
250/kg 
107.3±6.0 
*abcd 
2.3±0.9 
*abcd 
149.6±5.7 
*bcd 
6.6±2.1 
*bcd 
127.9±9.1 
*bcd 
4.3±1.3 
*bcd 
99.9±5.4 
*bcd 
1.8±0.0 
*bcd 
Note: *= significant at 5 % level (P<0.05), PC=plain control, R8=Rosiglitazone 8mg/kg, R16= Rosiglitazone 16mg/kg, G=glucose, 
I=insulin, a= plain control; b= Dexa control; c= Rosiglitazone 8mg/kg; d= Rosiglitazone 16mg/kg; e= C. zeylanicum bark extract 
250mg/kg, 
Table 4. Differences in means of fasting urine glucose and ketones on day 12 in dexamethasone 4mg and 8mg/kg series
Group 
n=6 
Urine Glucose (mmol/L) 
D4 series                   D8 series 
Urine ketones (mmol/L) 
D4 series                  D8 series 
Plain control Nil Nil Nil Nil 
Dexa control 14.1±3.7 76.6±1.2 1.5±0.5 10.6±4.1 
Rosi 8mg/kg 4.1±0.8*bd 20±3.0*bd Nil 1.1±0.2*b 
Rosi 16mg/kg 1.6±1.0*bc 11.6±2.1*bc Nil 2.3±1.2*b 
CZE 250mg/kg Nil Nil Nil Nil 
Note: *= significant at 5 % level (P<0.05), a= plain control; b= Dexa control; c= Rosiglitazone 8mg/kg; d= Rosiglitazone 16mg/kg; e= 
C. zeylanicum bark extract 250mg/kg.
Group 
n=6 
0min 
G                 I 
30min 
G                 I 
60min 
G                 I 
120min 
G                 I 
PC 83.3±7.9 0.7±0.0 147.8±3.9 5.7±1.4 131.9±9.5 4.6±1.8 100.8±5.4 2.6±0.5 
D4/kg 196.5±6.1 14.7±2.7 307.9±18.5 22.1±5.7 262.4±11.2 17.0±4.9 193.5±7.2 12.8±3.8 
R8/kg 
110.7±8.4 
*abe 
3.7±1.1 
*abe
 
174.2±13.7 
*abe
 
8.6±2.8 
*ab
 
152.1±6.5 
*abe
 
6.6±2.5 
*abe
 
106±4.3 
*b
 
3.5±1.7 
*be
 
R16/kg 
119.8±5.2 
*abe
 
4.6±1.3 
*abe
 
166.4±9.1 
*abe
 
9.0±3.1 
*ab
 
148.6±4.1 
*abe
 
7.1±4.1 
*abe
 
108.4±3.7 
*b
 
4.3±1.4 
*abe
 
CZE 
250/kg 
91.6±11.3 
*bcd
 
1.6±0.3 
*bcd
 
153.1±7.0 
*bcd
 
7.8±2.2 
*ab
 
125.8±3.6 
*bcd
 
5.4±1.9 
*bd
 
92.2±6.7 
*bcd
 
1.2±0.0 
*abcd
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DISCUSSION  
The present study was designed to investigate the potential 
effects of C. zeylanicum extract on dexamethasone induced 
insulin resistance emphasizing on its prevention in wistar albino 
rats. Dexamethasone is well recognized to cause hyperglycemia 
and whole body insulin resistance. Up to 2.5% of the population 
takes prescribed glucocorticoids and their side effects represent 
a considerable clinical burden.[11] In certain clinical conditions, 
dexamethasone needs to be administered in high doses and in 
such cases it causes adverse effects such as muscle catabolism, 
increased adiposity and increased insulin resistance.[12] The 
insulin resistance is mainly because of decrease in number of 
GLUT-1 transporter and decrease in GLUT-4 transporter 
translocation to plasma membrane.[13] Dexamethasone induces 
insulin resistance whether or not it induces hyperglycemia and 
whenever hyperglycemia is present, GLUT-2 positive β cell 
numbers, glucose transport into cells and insulin response to 
glucose are reduced.[14] 
Dexamethasone was chosen in the present study to induce 
insulin resistance as it is virtually devoid of mineralocorticoid 
actions.[13] Based on dose response curve of dexamethasone  
from the pilot study, a dose of 8mg/kg was chosen as it caused 
optimal insulin resistance which was measured by recording 
fasting insulin and fasting glucose. 4mg/kg dexamethasone was 
taken as the secondary dose as 16mg/kg caused severe weakness 
and intolerability in animals. It was observed that 4mg/kg 
dexamethasone produced a minimal rise in fasting glucose and 
insulin levels compared to 8mg/kg dexamethasone treatment 
groups throughout the study period which confirms that the 
insulin resistance is dose dependent. 
Cinnamon has been reported to have remarkable 
pharmacological effect in the treatment of insulin resistance. In 
the present study, 250mg/kg of aqueous extract of cinnamon 
bark significantly prevented the development of insulin 
resistance induced by dexamethasone. This was evidenced by a 
significant fall in fasting insulin and fasting glucose levels in 
CZE250mg/kg group compared to rosiglitazone and 
dexamethasone groups in both D4 and D8 series (Table2). 
Cinnamon bark extract acts probably by up-regulating 
expression of insulin receptors and promoting glucose 
metabolism in peripheral tissues in dexamethasone induced 
insulin resistance in rats as described by JiYeon Kim et al.[15] 
The primary chemical constituents of cinnamon include 
cinnamaldehyde, gum, tannin, mannitol, coumarins, essential 
oils (aldehydes, eugenol, pinene),[16] and it is evident that a 
substance in cinnamon called MHCP (methyl hydroxyl chalcone 
polymer) is mainly responsible for its beneficial results. MHCP 
closely resembles the insulin activity and acts synergistically 
with insulin in cells and further, MHCP treatment stimulated 
glucose uptake and glycogen synthesis to a similar level as 
insulin.[4] 
The fasting glucose and insulin in rosiglitazone group were 
significantly lowered compared to dexamethasone control in 
both D4 and D8 series (P<0.05) but the levels were significantly 
higher than CZE 250mg/kg treatment (P<0.05). However, the 
overall difference found between rosiglitazone 8 and 16mg/kg 
treatments was insignificant (P>0.05) (Table 2). 
IPGTT was performed to assess the overall utilization of glucose 
and post IPGTT glucose and insulin levels at 30 and 60min 
intervals in CZE250mg/kg group were reduced markedly 
compared to rosiglitazone and dexa control groups due to 
enhanced utilization of glucose at these intervals (Figure 2A-D). 
In vitro studies have shown that cinnamaldehyde which is an 
important chemical constituent of C. zeylanicum bark produces 
significant anti-hyperglycemic effect [17] and MHCP isolated 
from C. zeylanicumbark stimulates the autophosphorylation of 
the insulin receptor, glycogen synthesis and GS activity in 3T3-
L1 adipocytes also downregulates the GSK-3_ activity.  
Glycogen synthesis stimulation is through class I PI-3-K 
dependent pathway. [18] However, these intracellular actions of 
CZE250mg/kg favor the utilization of glucose and improve the 
insulin resistance caused by dexamethasone. 
The glycosuria was not completely reversed by rosiglitazone 
treatment when compared to CZE250mg/kg treatment, but, 
ketonuria was effectively reversed by both rosiglitazone and 
CZE250mg/kg in D4 series, not by rosiglitazone in D8 series 
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(Table 4). It is apparent from this study that rosiglitazone play 
limited role which may not be sufficient to improve higher 
degree of insulin resistance caused by dexamethasone. 
CONCLUSION 
The results found in this study reveal that, the aqueous extract 
of C. zeylanicum bark 250mg/kg has preventive effects on 
dexamethasone induced insulin resistance probably by 
enhancing peripheral uptake of glucose in to tissues and causing 
reduction in fasting glucose and insulin levels. Further 
evaluation should be undertaken to isolate and standardize these 
constituents for their efficacy and potency in insulin resistant 
animal models. 
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